Literature DB >> 18817530

Minimization of immunosuppression after lung transplantation: current trends.

Pamela J McShane1, Edward R Garrity.   

Abstract

This paper reviews efforts that have been made to minimize immunosuppression in lung transplant patients. A brief history of tolerance and its potential application to lung transplantation is also discussed.

Entities:  

Mesh：

Year:  2008        PMID： 18817530     DOI： 10.1111/j.1432-2277.2008.00764.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN： 0934-0874            Impact factor:   3.782


  4 in total

Review 1.  Myeloid-Derived Suppressor Cells and Their Potential Application in Transplantation.

Authors:  Joseph R Scalea; Young Suk Lee; Eduardo Davila; Jonathan S Bromberg
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

2.  Long term complications following 54 consecutive lung transplants.

Authors:  Walther Tabarelli; Hugo Bonatti; Dominique Tabarelli; Miriam Eller; Ludwig Müller; Elfriede Ruttmann; Cornelia Lass-Flörl; Clara Larcher; Christian Geltner
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

3.  Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway.

Authors:  Bo Zhu; Ai-Qun Ma; Lan Yang; Xiao-Min Dang
Journal:  Int J Mol Sci       Date:  2013-12-16       Impact factor: 5.923

4.  Bone marrow mesenchymal stem cells protect against bleomycin-induced pulmonary fibrosis in rat by activating Nrf2 signaling.

Authors:  Shirong Ni; Dexuan Wang; Xiaoxiao Qiu; Lingxia Pang; Zhangjuan Song; Kunyuan Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.